This content is from: Patents

Highlights from the March 2017 issue

Hard copies of our latest issue are now on their way to readers all over the world. But you don't need to wait for the post: subscribers can read the full contents online now!

MIP_March_17bigIf you have an individual or corporate subscription, log in with your username and password; contact my colleague Dan Bloomer if you need a reminder.

If you are not (yet) a subscriber you can still read up to five articles free of charge simply by registering your details.

Remember that there is much more content on the website and app than we can fit in the hard copy, and it's updated daily. 

New uses for known drugs

For example, our cover story this month features a discussion on the highly topical and contentious issue of second medical use patents. The full, unabridged, version is only available online

coverThe roundtable debate features contributions from both sides of the industry and the judiciary: the participants were Jurgen Dressel of Novartis Pharma; Galit Gonen of Teva; and Sir Robin Jacob, former Court of Appeal judge.

They discussed topics including: identifying the problem with new uses for known drugs, the role of patents and other IP rights, market segmentation, different national regulatory regimes, how to provide incentives, the approach of the courts and possible solutions. 

With big cases over drugs such as pregabalin before the courts, second medical use patents are important both legally and commercially, and this discussion is a must-read for anyone who works in the life science sector. 

Further reading

Design cases
Elsewhere in this issue, we have articles on developments in the US, Europe, Taiwan and Africa as well as several pieces focusing on strategic issues:
  • Our Americas editor Michael Loney reviews developments in 2016 at the US International Trade Commission, and looks at what 2017 may have in store.
  • In what has become a regular annual roundup, David Stone looks back at CJEU design cases in 2016. This is the first of two articles - the follow-up, looking at decisions due in 2017, will be online shortly. Look out also for a review of 2016 CJEU trade mark cases in our April issue.
  • Christopher M Neumeyer considers lessons to be learned from two recent cases where Taiwan companies were ordered to pay taxes on licensing fees paid to a foreign licensor.
  • In another article likely to be of use to IP managers, Nick McDonald considers how to keep your IP strategy alive and the consequences of failing to do so
  • In Africa, several governments have recently taken steps to tackle the serious counterfeiting challenge they face. Chris Walters explains more.
  • In the latest article in our occasional series on 3D printing issues, Stella Wong considers how new technology is causing disruption, notably in medical technology, and how companies can develop a 3DP strategy.

IP Stars and IP in verse

catsThe March issue also includes the second part of our annual IP Stars research, with the rankings of the top firms for patent work. We have a piece explaining the research and methodology, which includes a link to the full results on our sister website IP Stars.

You can now read the firm rankings for trade mark work, which were published last month. The remaining parts of the annual research, including the copyright rankings, individual IP Stars listings and firm analysis, will be available over the next few months.

As our Twitter followers may have seen, we had a bit of fun on Valentine's Day inviting readers to submit IP-related rhymes. Our diarist Utynam has selected some of the best (or worst, depending on your taste). Thanks to everyone who contributed.

International briefings

This month we have a bumper set of reports in our sponsored international briefings section, all of which are free to read:

The material on this site is for law firms, companies and other IP specialists. It is for information only. Please read our Terms and Conditions and Privacy Notice before using the site. All material subject to strictly enforced copyright laws.

© 2020 Euromoney Institutional Investor PLC. For help please see our FAQs.


Instant access to all of our content. Membership Options | One Week Trial